Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T08:37:13.287Z Has data issue: false hasContentIssue false
  • English
  • Français

Zetidoline, A New Antipsychotic

First Controlled Trial in Acute Schizophrenia

Published online by Cambridge University Press:  29 January 2018

T. Silverstone ,
S. Levine ,
H. L. Freeman  and
A. Dubini
T. Silverstone
Affiliation:
Medical College of St. Bartholomew's Hospital, German Hospital, Ritson Road, London E8 IDF
S. Levine
Affiliation:
Oldham and District General Hospital, Oldham
H. L. Freeman
Affiliation:
Hope Hospital, Salford
A. Dubini
Affiliation:
Lepetit Research Laboratories, Milan, Italy
Get access Rights & Permissions [Opens in a new window]

Summary

Zetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia. ZTD was found to be safe, as effective as HLP, and to produce significantly fewer extrapyramidal side-effects (EPS).

Type
Research Article
Information
The British Journal of Psychiatry , Volume 145 , Issue 3 , September 1984 , pp. 294 - 299
Copyright
Copyright © 1984 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barone, D., Corsico, N., Diena, A., Restelli, A. & Glasser, A. (1982) Biochemical and pharmacological activities of DL 308 IT: a new antidopaminergic agent. Journal of Pharmacy and Pharmacology, 34, 129–32.Google ScholarPubMed
Barone, D., Corsico, N., Diena, A. Difrancesco, G., Galliani, G., Landsberg, P., Pugnetti, P., Restelli, A. & Glasser, A. (1982). The unusual profile of action of DL 308, a potential anti-psychotic drug. In Advances in Human Psychopharmacology, selected papers from the 13th CINP Congress, Jerusalem 1982 (eds. Burrows, G. D. and Werry, J. S.). JAI Press Inc. (in press).Google Scholar
Donlon, P. T. & Stenson, R. L. (1973) Neuroleptic induced extrapyramidal symptoms. Diseases of the Nervous System, 37, 629–35.Google Scholar
Guy, W. (1976) Clinical Global Impression (CGI) In ECDEU Assessment Manual for Psychopharmacology, Revised 1976 U.S. Dept. of Health, Education and Welfare.Google Scholar
Johnstone, E. C., Crow, T. J., Frith, C. D., Carney, M. W. P., & Price, J. S. (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet, i, 848–51.Google Scholar
Montgomery, S. A. & Montgomery, D. B. (1980) Measurement of change in psychiatric illness: new obsessional, schizophrenia and depression scales. Postgraduate Medical Journal, 56 (suppl. 1), 50–2.Google ScholarPubMed
National Institute of Mental Health (NIMH) Psychopharmacology Service Center Collaborative Study Group (1964) Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry, 10, 246–61.Google Scholar
Perris, C., Andreoli, V., Kemali, D., Dubini, A., & Musch, B. (1982) ZTD (DL 308): a chemically new neuroleptic. A three center pilot clinical study. In Advances in Human Psychopharmacology, selected papers from the 13th CNIP Congress, Jerusalem 1982 (eds. Burrows, G. D. and Werry, J. S.). JAI Press, (in press).Google Scholar
Saletu, B., Grunberger, L., Linzmayer, L. & Dubini, A. Determination of the pharmacodynamics of the new neuroleptic ZTD by neuroendocrinological, pharmaco-EEG and psychometric studies. International Journal of Clinical Pharmacology, Therapy and Toxicology, (in press).Google Scholar
Sovner, R. & Dimascio, A. (1978) Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In Psychopharmacology. A Generation of Progress, (eds. Lipton, M. A., DiMascio, A., Killam, K. F.) New York: Raven Press.Google Scholar
Spitzer, R., Endicott, J. & Robins, E. (1975) Research Diagnostic Criteria Instrument no. 58, New York: New York State Psychiatric Institute.Google Scholar
Szabadi, E., Bradshaw, C. M. & Gaszner, P. (1980) The comparison of the effects of DL 308, a potential new neuroleptic agent, and thioridazine on some psychological and physiological functions in healthy volunteers. Psychopharmacology, 68, 125–34.Google Scholar
Wittenborn, J. R. (1977) Guidelines for Clinical trials of psychotropic drugs. Pharmakopsychiatrie-Neuropsychopharmakologie, 10, 205–32.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.